Inactivation of the tick-borne encephalitis virus by RNA-cleaving compounds

Elena P Goncharova1,2, Ludmila S Koroleva1,3, Vladimir N Silnikov1, Vladimir A Ternovoy2, Valentin V Vlassov1, Marina A Zenkova1*

1Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, 8, Lavrentiev Ave, 630090, Novosibirsk, Russian Federation, 2State Research Centre of Virology and Biotechnology VECTOR Rospotrebnadzor, 630559, Koltsovo, Novosibirsk region, Russian Federation, 3Novosibirsk State University, 2, Pirogov St, 530090 Novosibirsk, Russian Federation

*Correspondence to: Marina Zenkova, Email: marzen@niboch.nsc.ru, Tel: +7 383 3635160, Fax: +7 383 3635153

Received 22 October 2011; Revised 16 December 2011; Accepted 21 December 2011; Published 31 December 2011

© Copyright The Author(s): Published by Library Publishing Media. This is an open access article, published under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5). This license permits non-commercial use, distribution and reproduction of the article, provided the original work is appropriately acknowledged with correct citation details.

ABSTRACT

The tick-borne encephalitis virus (TBEV) is an RNA-containing enveloped virus, which poses a major threat to the well-being and health of humans. In this study, we describe an approach to the inactivation of TBEV, which involves the degradation of viral RNA by artificial ribonucleases (aRNases, small organic compounds that exhibit ribonuclease activity in vitro). We demonstrate that the incubation of TBEV with aRNases lead to the total inactivation of the virus as indicated by the plaque formation assay data, but retain the viral immunogenic properties, as shown by the ELISA data. We propose that a possible mechanism of TBEV inactivation with aRNase, which includes: i) formation of local breaks in the lipid membrane of the virus caused by aRNase, ii) penetration of aRNase into the viral capsid, iii) degradation of genomic RNA by aRNase. These data suggest that the proposed approach can be used in the production of killed-virus vaccine.

KEYWORDS: Artificial ribonucleases, RNA-containing viruses, tick-borne encephalitis, virus inactivation

INTRODUCTION

Viral diseases represent a global problem for public health worldwide. Among the most dangerous infectious agents for humans, are RNA viruses (Bray, 2008). These RNA-containing viruses are also the causal factor of a significant number of serious diseases within the animal (both domestic and wild) population. Highly-pathogenic RNA viruses such as aggressive strains of corona viruses (SARS), influenza, tick-borne encephalitis virus (TBEV) and dengue virus, represent a constant threat to the humanity (Gould and Solomon, 2008), and demand urgent diagnostics and treatment of these viruses.

TBEV (Flavivirus genus) is a single-stranded RNA virus with a spherical nucleocapsid surrounded by a host-derived lipid bilayer that contains 2 glycoproteins; membrane protein (M protein) and envelope protein (E protein). Exhibiting hemagglutination activity, E protein contains the major antigenic sites, which are responsible for inducing both the formation of neutralizing antibodies and the protective immune response within the infected organism (Maier et al, 2007).

Numerous studies have been carried out in order to explore various approaches concerning the development of antiviral compounds against pathogenic flaviviruses (Sampath and Padmanabhan, 2009). These include both the design of chemical compounds, which interfere with virus replication (Puig-Basagoiti et al, 2009), and compounds affecting specific pathways, crucial for the virus replication (Goodell et al, 2009). Although some of the previously
developed antivirals demonstrated potential, none of them were approved for use in humans. Presently, there are no approved antiviral therapeutics against TBEV.

Viral RNA is a potential target for the inactivation of TBEV, as its damage could abolish the virus replication. Herein, a new approach for the inactivation of TBEV by artificial ribonucleases (aRNases, low molecular weight compounds, capable of catalyzing the cleavage of RNA in vitro) was studied. Recently a number of aRNases were designed in the Institute of Chemical Biology and Fundamental Medicine (Novosibirsk, Russia) via the conjugation of RNA cleaving groups to nucleic acids binding molecules (Figure 1) (Konevets et al, 2001; Zenkova et al, 2001; Kovalev et al, 2008; Koroleva et al, 2008). These compounds display a pattern of RNA-cleavage similar to that of natural ribonuclease A (cleave RNA at 5'–C–A-3' and 5'–U–A-3' linkages) and do not interfere with biopolymers other than RNA. For instance, aRNase ABL3C3 built of imidazole-conjugated bis-quaternary salt of substituted 1,4-diazabicyclo[2.2.2] octane (DABCO) (Figure 1A) cleaves RNA under physiological conditions at Pyr-A motifs (Konevets et al, 1999; Zenkova et al, 2001). Another group contains the conjugates of peptide-like molecules with DABCO (R-D-2, K-D-1, Figure 1B and C, respectively) (Koroleva et al, 2005). The aRNase L2-3 is a peptide-mimicking compound, which is comprised of amino acids that are connected via the hydrophobic linker (Figure 1D). Finally, aRNase Dtr12 is a conjugate of two DABCO residues substituted with the aliphatic groups at bridge positions connected by a rigid linker, (Figure 1E) (Koroleva et al, 2008).

In order to produce safe and effective vaccines, it is essential to develop techniques that provide the complete inactivation of the virus and the preservation of its immunogenic activity. Since the modification of surface proteins during the inactivation strongly affects the immunogenic activity of the produced preparations, we investigated the ability of aRNases to penetrate via the viral envelope and to cleave the viral RNA resulting in the production of non-infectious virus preparation, characterized by the unaltered structure of the immunogenic sites.

The aRNases screening revealed compounds that are capable of inactivating the TBEV via the viral RNA cleavage; the study of the structure of the surface epitopes following inactivation was performed using monoclonal antibodies to surface E protein responsible for the immune response in vivo.

**MATERIALS AND METHODS**

**Cell culture and the virus**

Porcine kidney cells (PK) were maintained in Dulbecco minimum essential Medium (DMEM) (Sigma, USA) supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco BRL, Germany) at 37°C in a humidified atmosphere of 95% air and 5% CO\(_2\) (v/v). The TBE virus strain Sofjin was prepared by infecting PK cell culture; the supernatant was collected 2-3 days post infection and then stored at -70°C in aliquots.

**Plaque assay**

Virus titers were determined by plaque assay in PK cells growing in 24-well plates (Venturi et al, 2006). Briefly, the cells were plated in the 24-well culture plates (2×10\(^5\) cells per well) and allow to adhere overnight. Serial tenfold dilutions of the viral suspension were added to the cell monolayer; the cells were then incubated for 1hr at 37°C. After removal of the virus suspension the cells were washed with PBS and DMEM supplemented with 2% (v/v) FCS, 1% (v/v) carboxymethyl-cellulose (Sigma) was added to the well, and the cells were incubated for 72hr at 37°C. The plaques were visualized after 10% (v/v) formaldehyde fixation (1hr at room temperature) by staining with a 1% (v/v) crystal violet solution. The virus titer was estimated by counting the number of plaques observed in each well, and was expressed as plaque-formation unit per milliliter (PFU/ml).

**Cytotoxicity**

The cell viability was measured on the basis of the mitochondria-dependent reduction of MTT to formazan (Mosmann, 1983). PK cells were plated in the 96-well culture plates in 100µl DMEM with 10% (v/v) FBS as described above. Cells were incubated at 37°C in a humidified atmosphere with 5% (v/v) CO\(_2\) for 24hr to adhere. The medium in wells was then replaced by 100µl DMEM medium without FBS, containing different concentrations of aRNases (from 10\(^{-10}\) to 10\(^{-1}\) M) and cells were incubated in the presence of aRNases for 24hr at 37°C and 5% (v/v) CO\(_2\). MTT solution (10µl, 5mg/ml, Sigma) was then added to each well and the cells were incubated for 4hr at 37°C and 5% (v/v) CO\(_2\). Following incubation, the medium was removed and DMSO (100µl) was added to each well in order to dissolve the formazan crystals. The extent of MTT reduction to formazan was quantified by measurement of absorbance at 570nm, using Multiscan RC (Labsystems). All experimental points were run in four parallels. Results were represented as a percentage of living cells as compared to the control (untreated cells). The cell-inhibitory concentration (CC\(_{50}\)) was determined for each compound. Results are expressed as mean percentage values. The S.D. was below 5%.

**Inactivation of TBEV by aRNases in vitro**

Direct inactivation of TBEV by aRNases was examined by use of a plaques forming assay. The virus (1.5x10\(^4\) PFU) was incubated with various aRNases at concentrations ranging from 0.01µM to 1mM for 1hr at 37°C in 50 mM Tris-HCl, pH 7.0, containing 0.2M KCl and 0.2mM EDTA. The aRNases-treated virus was then used to infect monolayers of PK cell grown in 24-well plates for 1hr at 37°C. Following infection, the cells were treated as described above for the plaque assay. Standard placebo-treated virus controls, toxicity controls and normal medium controls were included in the assays.

**Inhibition of virus replication in the cell culture**

The aRNases-mediated inhibition of TBEV replication was evaluated in PK cells. Confluent monolayers of PK cells grown in 24-well plates were incubated with different concentrations of aRNases for 2hr at 37°C and 5% (v/v) CO\(_2\). Following this, the cells were infected with TBEV at a multiplicity of infection (MOI) of 0.1 PFU. After 1hr of incubation at 37°C and 5% (v/v) CO\(_2\), the medium containing both the non- absorbed virus and aRNase solution was either replaced with a new portion of culture medium, or not. The cells were then incubated for 48hr at 37°C and 5% (v/v) CO\(_2\). Following incubation, the culture medium was...
1mM of each dNTP in a buffer containing 10mM Tris-HCl (pH 8.0), 75mM KCl, 5mM MgCl₂, 10mM DTT in a total reaction volume of 20µl. Thereafter, cDNA was subjected to PCR amplification in 50µl reaction mixture containing 0.2mM dNTP mixture, 4mM MgSO₄, 0.15µM forward primer (5’-CGTGAACGTGTTGAGRAAAAGACAGC-3’), 0.15µM reverse primer (5’-TCAACACNAGY-CCTTTCGACACTCGTCW AGGRGGACCGCCC-BHQ1) collected, cleared by centrifugation at 400xg and 4°C and then subjected to the plaque assays.

Reverse transcription and PCR
Total RNA was isolated from virus suspension using RIBO-zol-A (FGUN CNIA Rospotrebnadzor). 1-2µg of total RNA was used for the preparation of cDNA with 2-2.5U of MMLV reverse transcriptase. The reaction was performed for 1hr at 37°C with hexanucleotide random primers and 1mM of each dNTP in a buffer containing 10mM Tris-HCl (pH 8.0), 75mM KCl, 5mM MgCl₂, 10mM DTT in a total reaction volume of 20µl. Thereafter, cDNA was subjected to PCR amplification in 50µl reaction mixture containing 0.2mM dNTP mixture, 4mM MgSO₄, 0.15µM forward primer (5’-CGTGAACGTGTTGAGRAAAAGACAGC-3’), 0.15µM reverse primer (5’-TCAACACNAGY-CCTTTCGACACTCGTCW AGGRGGACCGCCC-BHQ1), and 0.15µl of labelled probe (FAM-TCTTTCGACACTCGTCW AGGRGGACCGCCC-BHQ1).
and 1.5U/30µl Hot Start Taq DNA polymerase (Medi-
gen, Russia). The PCR reaction temperature profile was set at 95°C for 3min for the initial denaturation, followed by 45 cycles of 94°C for 10sec and 60°C for 40sec. The fluorescence signal was detected by “Rotor Gene 3000” (Corbett Research Pty Ltd.). The test Ct value was extrapolated against the standard curve. (derived from the sample of the virus incubated under the same conditions but without aRNases), in order to evaluate the amount of viral RNA present in each sample. The control sample, which was used for the construction of the standard curve, contained 10⁶ virus particles. The number of virus particles was defined by electron microscopy observations. The non-treated PK cells were used as a negative control.

**Enzyme-linked immunosorbent assay (ELISA)**

A 96-well ELISA plate was filled with 100µl of viral antigen diluted in 0.01M PBS pH 7.2 per well. Plates were incubated at 4°C overnight. On the following day plates were washed three times with a wash buffer (PBS with 0.05%, v/v, Tween-20; 300µl per well). All subsequent reagents added to the plates were diluted in the wash buffer containing 2% (v/v) FBS. After the addition of each reagent, the plates were incubated in humid air at 37°C for 1hr and subsequently washed three times. Monoclonal antibodies (mAbs) were serially diluted twofold from 1:100 to 1:12800 during assay. After incubation with serially diluted mAbs, plates were washed and incubated for 1hr at 37°C with peroxidase-conjugated goat anti-mouse antiserum. The wells were then washed again and the substrate of horse-radish peroxidase-o-phenylenediamine dihydrochloride was added. The colour reaction was stopped after 30min and the absorbance was measured at 492nm with Multiscan RC. MAbs titrated against the treated virus and compared to those obtained with intact virus.

**RESULTS**

**Inactivation of TBEV with aRNases**

The aRNases belonging to different aRNases series were tested in terms of their ability to inactivate TBEV *in vitro* and to prevent the viral infection development in cell culture. Figure 1 displays the structures of aRNases ABL3C3, R-D-2, K-D-1, Dtr12 and L2-3. All these compounds efficiently cleave the RNA substrate *in vitro* under physiological conditions (Konevets et al, 1999; Zenkova et al, 2001; Koroleva et al, 2005; Kovalev et al, 2008). The compounds are water soluble at millimolar concentrations.

The direct inactivation of TBEV by selected aRNases was investigated using the plaque assay method. The virus (1.5x10⁶ PFU) was incubated in the presence of chosen concentrations of aRNases for 18hr at 37°C in a buffer solution. After incubation, the treated TBEV was used to infect the monolayer of PK cells grown in 24-well plates, followed by the plaque assay. The results of these experiments are summarized in Table 1. It is clearly visible that incubation in the presence of aRNases significantly reduces the TBEV-induced plaque formation (less than 1 lg PFU/ml), thereby indicating a significant reduction of the number of viable viral particles in the aRNases-treated TBEV samples. It is worthy of note that aRNases exhibited antiviral activity at concentrations close to those at which efficient RNA cleavage occurred.

The cytotoxicity of aRNases in respect to the PK cells was evaluated using the MTT-test. Cells were incubated for 24hr in the presence of aRNases taken in concentrations from 0.1µM to 1mM and then the MTT assay was performed. CC⁵₀ values (i.e., concentrations of the compounds at which 50% of the cells remained viable) were determined from the concentration dependencies (Table 2). The aRNases of different series display different cytotoxicity: CC⁵₀ for L2-3 (2mM) and ABL3C3 (0.5mM) were found to be significantly higher than the corresponding values for other aRNases; thereby indicating the considerably low cytotoxicity of these compounds. aRNases R-D-2 and K-D-2 having a similar structure display moderate cytotoxicity: CC⁵₀ is 0.15mM; aRNase Dtr12 was the most toxic (CC⁵₀ 0.07mM). These CC⁵₀ values for aRNases tested were significantly higher than the optimal concentrations of aRNases for *in vitro* cleavage of RNA substrate (see Table 1).

In another set of experiments the effect of the aRNases on TBEV propagation in the PK cell culture was studied. In these experiments PK cells were incubated in the presence of varying concentrations of aRNases for 2hr. Following this, the cells were infected with the virus at MOI 0.1 PFU. The number of infectious virus particles released from the cells

| aRNase | Optimal concentration of aRNases for *in vitro* RNA cleavage, mM | Concentrations of aRNases used for inactivation of TBEV, mM | TBEV titer, lg(PFU/ml)** |
|--------|---------------------------------------------------------------|---------------------------------------------------------------|--------------------------|
| ABL3C3 | 0.1                                                           | 0.5                                                           | <1                       |
| R-D-2  | 0.1                                                           | 0.06                                                          | <1                       |
| K-D-1  | 0.1                                                           | 0.06                                                          | <1                       |
| Dtr12  | 0.01                                                          | 0.02                                                          | <1                       |
| L2-3   | 1                                                             | 2                                                             | <1                       |
| Negative control* | -                               | -                                                             | 4.2                       |

*Titer of TBEV incubated for 18hr at 37°C in the absence of aRNases. Initial titer of TBEV preparation was 6.1 lg (PFU/ml)

**Viral titer was measured following TBEV incubation with aRNases for 18hr at 37°C."
and mAbs 13F6 and E6B specific to the region 273-429 (Figure 2), in order to detect possible changes in the antigen specificity of the envelope. The obtained results (in Figure 2 the date are shown for mAbs 4F6 and 13F6, similar results were obtained for mAbs 10H10 and E6B) indicate that monoclonal antibodies exhibit a similar affinity to the specific regions of the E protein of both the control (no treatment) and aRNase-inactivated TBEV. Closely adjacent curves point to the undamaged state of the antigenic determinants (Karavanov et al, 1990). These experiments confirm the preservation of the structural integrity of envelope protein E upon TBEV inactivation with aRNases.

It is interesting to note that the incubation of TBEV with aRNase ABL3C3 even improves the binding of the inactivated viral particles with the monoclonal antibodies 13F6 (Figure 1B).

### Effect of aRNAases on genomic RNA of TBEV

The main idea of applying aRNase as antiviral agents was to destroy specifically viral RNA. To confirm the mechanism of aRNAse-mediated TBEV inactivation the integrity and amount of viral RNA in aRNAse-inactivated virus preparations was ascertained by real-time PCR. TBEV was inactivated by aRNAse (concentration of the compounds used for TBEV inactivation are shown in Table 1). Viral RNA was isolated from the virus preparations and was used as a template in reverse-transcription/real-time PCR analysis. Figure 3 displays the relative amounts of viral RNAs in the preparation of aRNAse-inactivated TBEV; the level of viral RNA in the control (untreated virus) was set at 100%. It is clearly apparent that the significant reduction of viral RNA amount is observed in TBEV samples treated with aRNAse Dtr12. In the case of treatment with ABL3C3, a reliable reduction of viral RNA amount is observed in comparison with the control virus. In the virus preparations inactivated with aRNAse R-D-2 and K-D-1 no noticeable changes in the level of viral RNA were detected. However, TBEV titer in these preparations was less than 1 lg PFU/ml – in other words, the virus was entirely inactivated. It is possible that in the case of aRNAse R-D-2 and K-D-1, the virus was not inactivated, but the viral RNA was degraded into nucleotides.

### Table 2. Effect of aRNAse on TBEV propagation in PK cells.

| aRNAse   | CC₅₀*, mM | Concentrations of aRNAse used for inactivation of TBEV, mM | Titer of TBEV**, lg(PFU/ml) |
|----------|-----------|----------------------------------------------------------|-----------------------------|
| R-D-2    | 0.15      | 0.06                                                     | 7.4                         |
| K-D-1    | 0.15      | 0.06                                                     | 5.8                         |
| Dtr12    | 0.07      | 0.02                                                     | 6.7                         |
| ABL3C3   | 0.5       | 0.25                                                     | 6.0                         |
| L2-3     | 2         | 1                                                       | 6.7                         |
| Negative control*** | - | 7.5                  |

*CC₅₀: Concentration of the aRNAse at which 50% PK cells remains viable (MTT assay data)

**Titer of TBEV 48hr post infection of PK cells incubated for 2hr in the presence of aRNAse prior to infection with TBEV at a MOI of 0.1 PFU.

***TBEV incubated for 48hr at 37°C in absence of aRNAse, lg(PFU/ml)

Interestingly, the inhibitory effect of aRNAse was higher in the presence of aRNAse in the culture medium during the development of TBEV infection than when the cell medium containing aRNAse and virus was replaced 1hr post infection (see Experimental section for details) by fresh portion of the medium. Under these conditions (aRNAse containing cell medium was replaced by fresh portion) aRNAse K-D-1 reduces the progeny virus titer by only -0.5 lg (PFU/ml) in comparison to the control, and other aRNAse display no antiviral activity under this conditions (primary data not shown). The enhancement of the inhibitory effect in the presence of aRNAse in the culture medium might result from the direct inactivation of the virus released from infected cells. Consequently, the assay used did not permit the precise discrimination between antiviral and virucidal effects of aRNAse because we could not exclude the possibility that the aRNAse could penetrate into the cells and interfere with the intracellular steps of the viral cycle.

### Antigen specificity of the envelope protein E of the aRNAse-inactivated TBEV

We explored whether aRNAse affect the structure of the surface epitope of envelope virus protein. ELISAs were performed using two types of monoclonal antibodies: (mAbs) 4F6 and 10H10 specific to the region of the E protein 19-273 and mAbs 13F6 and E6B specific to the region 273-429 (Figure 2), in order to detect possible changes in the antigen specificity of the envelope. The obtained results (in Figure 2 the date are shown for mAbs 4F6 and 13F6, similar results were obtained for mAbs 10H10 and E6B) indicate that monoclonal antibodies exhibit a similar affinity to the specific regions of the E protein of both the control (no treatment) and aRNase-inactivated TBEV. Closely adjacent curves point to the undamaged state of the antigenic determinants (Karavanov et al, 1990). These experiments confirm the preservation of the structural integrity of envelope protein E upon TBEV inactivation with aRNAse. It is interesting to note that the incubation of TBEV with aRNAse ABL3C3 even improves the binding of the inactivated viral particles with the monoclonal antibodies 13F6 (Figure 1B).

**Effect of aRNAse on genomic RNA of TBEV**

The main idea of applying aRNAse as antiviral agents was to destroy specifically viral RNA. To confirm the mechanism of aRNAse-mediated TBEV inactivation the integrity and amount of viral RNA in aRNAse-inactivated virus preparations was ascertained by real-time PCR. TBEV was inactivated by aRNAse (concentration of the compounds used for TBEV inactivation are shown in Table 1). Viral RNA was isolated from the virus preparations and was used as a template in reverse-transcription/real-time PCR analysis. Figure 3 displays the relative amounts of viral RNAs in the preparation of aRNAse-inactivated TBEV; the level of viral RNA in the control (untreated virus) was set at 100%. It is clearly apparent that the significant reduction of viral RNA amount is observed in TBEV samples treated with aRNAse Dtr12. In the case of treatment with ABL3C3, a reliable reduction of viral RNA amount is observed in comparison with the control virus. In the virus preparations inactivated with aRNAse R-D-2 and K-D-1 no noticeable changes in the level of viral RNA were detected. However, TBEV titer in these preparations was less than 1 lg PFU/ml – in other words, the virus was entirely inactivated. It is possible that in the case of aRNAse R-D-2 and K-D-1, the virus was not inactivated, but the viral RNA was degraded into nucleotides.

©The Authors | Journal of Molecular and Genetic Medicine | 2011 | Vol 5 | 266-272 | OPEN ACCESS
and low cost of the synthesis of aRNases combined with low toxicity of the compounds make aRNases attractive agents for virus inaction.

aRNases can be used for the inactivation of different RNA-containing viruses, including those from Flaviviridae family, the propagation of which poses an apparent threat to human health. At present, the general procedure for flavivirus inactivation is used on formaldehyde solution application (Ehrlich et al, 2003). However, the search for new non-toxic drugs is in progress (Meneses et al, 2009; Zhang et al, 2009).

Recently, we reported on the efficient inactivation of the influenza virus by aRNase ABL3C3 (Goncharova et al, 2009) and Acute Bee Paralysis Virus (ABPV) by D3-12, Dp12F6 and K-D-1 (Fedorova et al, 2011). In the present study, the effect of five aRNases on the tick-borne encephalitis virus (TBEV) was investigated. It was found that aRNases having different chemical structures can act as effective inhibitors of TBEV: Incubation in the presence of aRNases for 18hr at 37°C results in the complete inactivation of the virus (Table 1). Along with the ability of all tested aRNases to inactivate TBEV particles, the inhibiting action of aRNases on virus propagation in cell culture in vitro (Table 2) was also observed. The maximal inhibiting activity was displayed by aRNase K-D-1 (in the presence of this compound the virus titer was decreased by 1.7 log PFU/ml). Other aRNases tested displayed lower virus inhibiting effects. Thus, aRNases exhibited both virucidal and antiviral activities.

The integrity of genomic RNA in the inactivated virus preparations using real-time PCR (the length of amplified fragment was 137 nucleotides) was analyzed, in order to validate the putative mechanism of the virus inactivation by aRNases which was shown to be viral RNA cleavage in the
case of Influenza virus and ABPV (Goncharova et al, 2009; Fedorova et al, 2011) (Figure 3). The obtained results reveal that the degradation of viral RNA was observed in TBEV preparations, which were inactivated by Dtr12, while in the ABL3C3-, R-D-2- and K-D-1-inactivated TBEV preparations the levels of viral RNA remained unaltered. It is likely that in the latter case, other regions of viral RNA than those amplified were cleaved. It is worth of note that even a single cut of TBEV genomic RNA (10480 nucleotides) could lead to virus inactivation. Conversely, aRNases used in this study are amphiphiles with the exception of L-2-3 and have the ability to disrupt the viral membrane that could also cause the virus inactivation.

An essential requirement for the effective preparation of inactivated vaccines is the conservation of the ability of viral proteins to cause the immune response initiation. We evaluated the influence of aRNases treatment on the immunogenic properties of TBEV envelope E antigen using a set of monoclonal antibodies against separate epitopes of this protein. Our results provide evidence that the virus - antibodies interactions were not altered upon incubation with aRNases. Interestingly, in the presence of aRNase ABL3C3 we observed an even higher level of virus binding with the 13F6 antibody that can be explained by the possible partial release of the protein from the viral membrane due to the ability of ABL3C3 to cause disruption of the viral membrane (Goncharova et al, 2009).

In conclusion, our experiments with different aRNases revealed their ability to inactivate the TBEV in vitro. The virus inhibition effect correlated with the destruction of viral RNA for two aRNases from the test list. Inactivation of TBEV upon aRNases treatment was not accompanied by antigenic determinants degradation of the viral envelope protein E. The data obtained earlier in experiments with the influenza virus evidence the ability of the tested aRNases to inactivate various RNA-containing viruses. Our results confirm that aRNases can be considered as potential agents for inactivated vaccine preparation from viruses with the RNA genome. Furthermore, due to the observed low toxicity and ability to inactivate the TBEV for the aRNase K-D-1, more detailed studies are needed to evaluate the potential of this compound as anti-TBEV therapeutic agent.

ACKNOWLEDGEMENTS

The authors acknowledge Mrs. Albina V. Vladimirova (Institute of Chemical Biology and Fundamental Medicine SB RAS) for the maintenance of cells. This research was supported by the Russian Academy of Science under the programs “Molecular and Cellular Biology”, “Science to Medicine”, and the President’s program in support of leading scientific schools (SS-7101.2010.4), The Russian Foundation for Basic Research (Grant Numbers 08-04-01415a and 09-04-01483), and by Ministry of Science and Education of the Russian Federation (State contract Number 16.N08.12.1005).

STATEMENT OF COMPETING INTERESTS

None declared.

REFERENCES

Bray M. 2008. Highly pathogenic RNA viral infections: Challenges for antiviral research. Antiviral Res, 78, 1-8.
Ehrlich HJ, Pavlova BG, Fritsch S et al. 2003. Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine, 22, 217-223.
Fedorova AA, Azzanni K, Ryabchikova EI et al. 2011. Inactivation of a non-enveloped RNA virus by artificial ribonucleases: honey bees and acute bee paralysis virus as a new experimental model for in vivo antiviral activity assessment. Antiviral Res, 91, 267-277.
Giampieri M, Balbi A, Mazzei M et al. 2009. Antiviral activity of indole derivatives. Antiviral Research, 83, 179-185.
Goncharova EP, Kyppak MP, Ryabchikova EI et al. 2009. Viral genome cleavage with artificial ribonucleases: a new method to inactivate RNA-containing viruses. Dokl Biochem Biophys, 427, P221-224.
Goodell JR, Puig-Basagoiti F, Forshey BM et al. 2006. Identification of compounds with anti-West Nile virus activity. J Med Chem, 49, 2127-2137.
Gould EA, Solomon T. 2008. Pathogenic flaviviruses. Lancet, 371, 500-509.
Karavanov AS, Matveev LE, Rubin GG et al. 1990. Identification of individual antigenic epitopes of the envelope protein in the tick-borne encephalitis virus using monoclonal antibodies. Vopr Virusol, 35, 140-143.
Konevtsz DA, Beck IE, Beloglovzaja NG et al. 1999. Artificial ribonucleases: synthesis and RNA cleaving properties of cationic conjugates bearing imidazole residues. Tetrahedron, 55, 503-514.
Koroleva LS, Donina AA, Tamkovich NV et al. 2005. Artificial ribonucleases 6. Ribonuclease activity of tetrapeptides based on amino acids involved in the catalytic site of RNase T1. Russ Chem Bull, 54, 2682-2691.
Koroleva LS, Kuz’min VE, Muraven OT et al. 2008 Artificial ribonucleases: quantitative analysis of the structure–activity relationship and a new insight into the strategy of design of highly efficient RNase mimetics. Russ. J. Bioorg. Chem, 34, 442-452.
Koroleva LS, Serpokrylova IYu, Vlassov VV et al. 2007 Design and synthesis of metal-free artificial ribonucleases. Protein & Peptide Letters, 14, 151-163.
Kovaliev N, Medvedeva D, Zenkova M, Vlassov V. 2008. Cleavage of RNA by an amphiphilic compound lacking traditional catalytic groups. Bioorganic Chemistry, 36, 33-45.
Maier CC, Delagrace S, Zhang Z et al. 2007. A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. Virology, 362, 468-474.
Meneses R, Ocaizacione R, Martinez J, Stashenko E. 2009. Inhibitory effect of essential oils obtained from plants grown in Colombia on yellow fever virus replication in vitro. Ann. Clin Microbiol Antiimicrob, 8, 5.
Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63.
Puig-Basagoiti F, Qing M, Dong H et al. 2009. Identification and characterization of inhibitors of West Nile virus. Antiviral Res, 83, 71-79.
Sampath A, Padmanabhan R. 2009. Molecular targets for flavivirus drug discovery. Antiviral Res, 81, 6-15.
Sebastian L, Desai A, Shampur M, Peruma Y, Sriman D, Vasan-thapuram R. 2008. N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo. Virology Journal, 5, 64-76.
Venturi G, Mel R, Marchi A et al. 2006. Humoral immunity and correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis virus in children. J Virol Methods, 134, 136-139.
Zenkova MA, Sil’nikov VN, Beloglovzaja NG, Giegé R and Vlassov VV. 2001. RNA Cleaving 1,4-diazabicyclo[2.2.2]octane-Imidazole Conjugates. Meth. Enzmol., 341, 468-490.
Zhang X, Mason P, Dubovi E et al. 2009. Antiviral activity of geneticin against dengue virus. Antiviral Research, 83, 21-27.